Degarelix: A gonadotropin-releasing hormone antagonist for the management of prostate cancer

Clinical Therapeutics

Volumn 31, Issue PART. 2, 2009, Pages 2312-2331

  Steinberg, Michael ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

degarelix; GnRH; GnRH antagonist; prostate cancer

Indexed keywords

ABARELIX; DEGARELIX; FIRMAGON; GONADORELIN; LEUPRORELIN; LUTEINIZING HORMONE; PLACEBO; TESTOSTERONE; TRIPTORELIN; UNCLASSIFIED DRUG;

ANDROGEN DEFICIENCY; ARTICLE; BACKACHE; CANCER THERAPY; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; COST EFFECTIVENESS ANALYSIS; COUGHING; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GONADORELIN RELEASE; HORMONE INHIBITION; HOT FLUSH; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; LOADING DRUG DOSE; LUTEINIZING HORMONE BLOOD LEVEL; LUTEINIZING HORMONE RELEASE; NONHUMAN; PROSTATE CANCER; SIDE EFFECT; SINGLE DRUG DOSE; TESTOSTERONE BLOOD LEVEL; TESTOSTERONE RELEASE; URINARY TRACT INFECTION; WEIGHT GAIN;

DOSE-RESPONSE RELATIONSHIP, DRUG; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; MALE; OLIGOPEPTIDES; PROSTATIC NEOPLASMS;

EID: 74749105209     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.11.009     Document Type: Article

References (47)

1. American Cancer Society (ACS). Cancer facts & figures (2008). http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf Accessed October 3, 2009
2. American Cancer Society (ACS). American Cancer Society guidelines for the early detection of cancer. http://www.cancer.org/docroot/ped/content/ped_2_3x_acs_cancer_detection_ guidelines_36.asp Accessed October 3, 2009
3. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Prostate cancer- V1.2009. http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf Accessed October 3, 2009
4. Firmagon (degarelix) [prescribing information] (2009), Ferring Pharmaceuticals, Inc, Parsippany, NJ
5. Parker K.L., and Schimmer B.P. Pituitary hormones and their hypothalamic releasing hormones. In: Brunton L.L., Lazo J.S., and Parker K.L. (Eds). Goodman & Gilman's: The Pharmacological Basis of Therapeutics. 11th ed. (2006), McGraw-Hill, New York, NY
6. Ganirelix acetate injection [prescribing information]. (2008), Organon USA Inc, Roseland, NJ. http://www.spfiles.com/piganirelix.pdf Accessed October 3, 2009
7. Huhtaniemi I., White R., McArdle C.A., and Persson B.E. Will GnRH antagonists improve prostate cancer treatment?. Trends Endocrinol Metab. 20 (2008) 43-50
8. Broqua P., Riviere P.J., Conn P.M., et al. Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: Degarelix. J Pharmacol Exp Ther. 301 (2002) 95-102
9. Cetrotide (cetrorelix acetate for injection) [prescribing information] (2008), EMD Serono, Inc, Rockland, Mass. http://www.emdserono.com/cmg.emdserono_us/en/images/Cetrotide_tcm115_193 46.pdf Accessed October 10, 2009
10. Praecis Pharmaceuticals Incorporated announces strategic restructuring and refocusing of company operations [press release] (May 20, 2005), Praecis Pharmaceuticals, Inc. http://phx.corporate-ir.net/phoenix.zhtml?c=83723&p=irol-newsArticle &t=Regular&id=712155& Accessed October 10, 2009
11. Rivier J., Porter J., Hoeger C., et al. Gonadotropin-releasing hormone antagonists with N omegatriazolylornithine, -lysine, or -paminophenylalanine residues at positions 5 and 6. J Med Chem. 35 (1992) 4270-4278
12. Samant M.P., Hong D.J., Croston G., et al. Novel gonadotropin-releasing hormone antagonists with substitutions at position 5. Biopolymers. 80 (2005) 386-391
13. Zelefsky M.J., Eastham J.A., Sartor O.A., et al. Cancer of the prostate. In: DeVita Jr. V.T., Lawrence T.S., and Rosenberg S.A. (Eds). DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 8th ed. (2008), Wolters Kluwer-Lippincott Williams & Wilkins, Philadelphia, Pa
14. Sakr W.A., Grignon D.J., Crissman J.D., et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: An autopsy study of 249 cases. In Vivo. 8 (1994) 439-443
15. National Cancer Institute. Surveillance Epidemiology and End Results. SEER stat fact sheets. http://seer.cancer.gov/statfacts/html/prost.html Accessed October 3, 2009.
16. Ross R.K., Bernstein L., Lobo R.A., et al. 5-Alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet. 339 (1992) 887-889
17. Lim L.S., Sherin K., and ACPM Prevention Practice Committee. Screening for prostate cancer in U.S. men. ACPM position statement on preventive practice [published correction appears in Am J Prev Med. 2008;34:454]. Am J Prev Med. 34 (2008) 164-170
18. Gleason D.F. The Veteran's Administration Cooperative Urologic Re- search Group: Histologic grading and clinical staging of prostatic carcinoma. In: Tannenbaum M. (Ed). Urologic Pathology: The Prostate (1977), Lea and Febiger, Philadelphia, Pa 171-198
19. Gleason D.F. Histologic grade, clinical stage, and patient age in prostate cancer. NCI Monogr. 7 (1988) 15-18
20. Scher H.I. Prostate cancer. In: Fauci A.S. (Ed). Harrison's Principles of Internal Medicine. 17th ed. (2008), McGraw-Hill Medical, New York, NY
21. Chen Y., and Sawyers C.L. Molecular biology of prostate cancer. In: DeVita Jr. V.T., Lawrence T.S., and Rosenberg S.A. (Eds). DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 8th ed. (2008), Wolters Kluwer-Lippincott Williams & Wilkins, Philadelphia, Pa
22. Griffin J.E. Androgen resistance-the clinical and molecular spectrum. N Engl J Med. 326 (1992) 611-618
23. Gittelman M., Pommerville P.J., Persson B.E., et al. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. J Urol. 180 (2008) 1986-1992
24. Gittelman M., Pommerville P., De La Rosette J., et al., Degarelix Study Groups. Degarelix: A gonadotropinreleasing hormone receptor (GnRH) blocker, tested in two one-year multicenter, randomized, dose-finding studies in prostate cancer patients. J Clin Oncol. 24 Suppl (2006) 14516. http://meeting.ascopubs.org/cgi/content/abstract/24/18_suppl/14516 2006 ASCO Annual Meeting Proceedings. Accessed October 10, 2009
25. Van Poppel H., Tombal B., de la Rosette J.J., et al. Degarelix: A novel gonadotropin-releasing hormone (GnRH) receptor blocker-results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. Eur Urol. 54 (2008) 805-813
26. Klotz L., Boccon-Gibod L., Shore N.D., et al. The efficacy and safety of degarelix: A 12-month, comparative, randomized, open-label, parallelgroup phase III study in patients with prostate cancer. BJU Int. 102 (2008) 1531-1538
27. Ferring Pharmaceuticals. FDA approves Ferring Pharmaceuticals' degarelix (generic name) for treatment of advanced prostate cancer [press release] (December 24, 2008). http://www.ferringusa.com/news_and_events/view/37 Accessed October 10, 2009
28. Dal Prato L., Borini A., Cattoli M., et al. GnRH analogs: Depot versus short formulations. Eur J Obstet Gynecol Reprod Biol. 115 Suppl 1 (2004) S40-S43
29. Sorbera L.A., Bolos J., Serradell N., and Bayes H. Degarelix acetate. Drugs Future. 31 (2006) 755-766
30. Jiang G., Stalewski J., Galyean R., et al. GnRH antagonists: A new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6. J Med Chem. 44 (2001) 453-467
31. White R., Schwach G., and Schteingart C.D. Degarelix, a unique, sustainedrelease depot GnRH blocker with a long duration of action. Presented at: World Congress on Controversies in Urology. Barcelona, Spain (January 31-February 3, 2008). http://www.comtecmed.com/cury/Document.aspx?did=74 Accessed October 3, 2009
32. Tornøe C.W., Agersø H., Senderovitz T., et al. Population pharmacokinetic/ pharmacodynamic (PK/PD) modelling of the hypothalamic-pituitarygonadal axis following treatment with GnRH analogues. Br J Clin Pharmacol. 63 (2007) 648-664
33. Svensson U.S., Senderovitz T., and Karlsson M.O. Population PK/PD modeling of testosterone (T), LH and dihydrotestosterone (DHT) response to single SC degarelix in male volunteers. Clin Pharmacol Ther. 73 (2003) P87
34. Tornøe C.W., Agersø H., Nielsen H.A., et al. Population pharmacokinetic modeling of a subcutaneous depot for GnRH antagonist degarelix. Pharm Res. 21 (2004) 574-584
35. Jadhav P.R., Agersø H., Tornøe C.W., and Gobburu J.V. Semi-mechanistic pharmacodynamic modeling for degarelix, a novel gonadotropin releasing hormone (GnRH) blocker. J Pharmacokinet Pharmacodyn 33 (2006) 609-634
36. Princivalle M., Broqua P., White R., et al. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropinreleasing hormone antagonist. J Pharmacol Exp Ther. 320 (2007) 1113-1118
37. Tammela T., Iversen P., Johansson J., et al. Degarelix - a phase II multicentre, randomized dose-escalating study testing a novel GnRH receptor blocker in prostate cancer patients. Eur Urol Suppl. 4 (2005) 228
38. Oken M.M., Creech R.H., Tormey D.C., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 5 (1982) 649-655
39. Firmagon® (degarelix) is launched in Europe for the treatment of advanced prostate cancer [press release] (March 18, 2009), Ferring Pharmaceuticals, Inc. http://www.ferring.com Accessed May 11, 2009
40. Physicians' Desk Reference 2009. 63rd ed. Vol. 28 (2009), Thomson Reuters, Montvale, NJ
41. ClinicalTrials.gov. A comparative study of degarelix three-month depot in three different dosing regimens in patients with prostate cancer. Identifier NCT00116753. Study number FE200486 CS15. http://clinicaltrials.gov/ct2/show/nct00116753?term=degarelix&rank=3 Accessed October 3, 2009
42. ClinicalTrials.gov. A parallel group comparison of the efficacy and safety of degarelix at two different dosing regimens in patients with prostate cancer. Identifier NCT00116779. Study number FE200486 CS14. http://clinicaltrials.gov/ct2/show/NCT00116779?term=degarelix&rank=1 6 Accessed October 3, 2009
43. ClinicalTrials.gov. Open-label, randomised parallel-group study. Identifier NCT00728533. Study ID number FE200486 CS26, 2007-0060055-39. http://clinicaltrials.gov/ct2/show/NCT00728533?term=degarelix&rank=4 Accessed October 3, 2009
44. ClinicalTrials.gov. Investigating efficacy and safety of two degarelix three-month dosing regimens in patients with prostate cancer requiring androgen ablation therapy. Identifier NCT00468286. Study number FE200486 CS18. http://clinicaltrials.gov/ct2/show/NCT00468286?term=degarelix&rank=5 Accessed October 3, 2009
45. ClinicalTrials.gov. A study evaluating a one-month dosing regimen of degarelix in prostate cancer requiring androgen ablation therapy (ICHGCP). Identifier NCT00451958. Study number FE200486 CS21A. http://clinicaltrials.gov/ct2/show/NCT00451958?term=degarelix&rank=7 Accessed October 3, 2009
46. ClinicalTrials.gov. Degarelix as second-line hormonal treatment after prostate-specific antigen (PSA)- failure in GnRH agonist treated patients with prostate cancer. Identifier NCT00738673. Study number FE200486 CS27. http://clinicaltrials.gov/ct2/show/NCT00738673?term=degarelix&rank=1 5 Accessed October 3, 2009
47. ClinicalTrials.gov. An extension study evaluating the long-term safety and tolerability of degarelix onemonth depots in prostate cancer. Identifier NCT00215683. Study number FE200486 CS12A. http://clinicaltrials.gov/ct2/show/NCT00215683?term=degarelix&rank=8 Accessed October 3, 2009